secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2026-05-14T11:02:34+00:00
Accession:  0001193125-26-222746
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar plans rolling BLA for nomlabofusp in June 2026; Q1 net loss $29.6M
--------------------------------------------------------------------------

- Net loss Q1 2026 $29.6M ($0.31/sh) vs Q1 2025 $29.3M ($0.46/sh). Cash $200.4M.
- Intends to initiate rolling BLA seeking accelerated approval June 2026; CMC module H2 2026.
- Topline open-label study data expected Q2 2026; Phase 3 first patient dose mid-2026.
- Breakthrough Therapy Designation granted Feb 2026. Skin frataxin as surrogate endpoint supported by published data.
- Feb 2026 $115M public offering extended cash runway into Q2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/0001193125-26-222746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526222746/lrmr-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-222746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer